{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:31:21Z","timestamp":1767893481422,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T00:00:00Z","timestamp":1446249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s13277-015-4290-5","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T21:16:49Z","timestamp":1446326209000},"page":"4813-4829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["HNF1\u03b2 drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)"],"prefix":"10.1007","volume":"37","author":[{"given":"Filipa","family":"Lopes-Coelho","sequence":"first","affiliation":[]},{"given":"Sofia","family":"Gouveia-Fernandes","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds G","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Carolina","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Faustino","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Ana","family":"F\u00e9lix","sequence":"additional","affiliation":[]},{"given":"Sofia A","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Jacinta","family":"Serpa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,10,31]]},"reference":[{"key":"4290_CR1","doi-asserted-by":"crossref","unstructured":"Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 2001;38:87\u201395. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11207821 .","DOI":"10.1046\/j.1365-2559.2001.01042.x"},{"key":"4290_CR2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. Cancer J Clin. 2012;62:10\u201329.","journal-title":"Cancer J. Clin"},{"key":"4290_CR3","doi-asserted-by":"crossref","unstructured":"Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10861437 .","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5"},{"key":"4290_CR4","first-page":"517","volume":"123","author":"RGW Verhaak","year":"2013","unstructured":"Verhaak RGW, Tamayo P, Yang J, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123:517\u201325.","journal-title":"J Clin Invest"},{"key":"4290_CR5","doi-asserted-by":"crossref","unstructured":"Del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecologic oncology [Internet]. Elsevier Inc.; 2012 [cited 2015 Jan 29];126:481\u201390. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22525820","DOI":"10.1016\/j.ygyno.2012.04.021"},{"key":"4290_CR6","first-page":"10","volume":"3","author":"C Gates","year":"2014","unstructured":"Gates C, Rice VM. Epithelial ovarian cancer: an overview. World J Transl Med. 2014;3:10\u201329.","journal-title":"World J Transl Med"},{"key":"4290_CR7","doi-asserted-by":"crossref","unstructured":"Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:5404\u201313. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2743856&tool=pmcentrez&rendertype=abstract .","DOI":"10.1158\/1078-0432.CCR-09-0365"},{"key":"4290_CR8","unstructured":"Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013;4."},{"key":"4290_CR9","doi-asserted-by":"crossref","unstructured":"Lee Y-Y, Kim T-J, Kim M-J, Kim H-J, Song T, Kim MK, et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecologic oncology [Internet]. Elsevier Inc.; 2011 [cited 2015 Feb 27];122:541\u20137. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21640372","DOI":"10.1016\/j.ygyno.2011.05.009"},{"key":"4290_CR10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1525-1438.2005.15305.x","volume":"15","author":"S Pather","year":"2005","unstructured":"Pather S, Quinn MA. Clear-cell cancer of the ovary\u2014is it chemosensitive ? Int J Gynecol Cancer. 2005;15:432\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"4290_CR11","doi-asserted-by":"crossref","unstructured":"Anglesio MS, Carey MS, K\u00f6bel M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic oncology [Internet]. Elsevier Inc.; 2011 [cited 2013 Sep 22];121:407\u201315. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21276610","DOI":"10.1016\/j.ygyno.2011.01.005"},{"key":"4290_CR12","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos PA, Matulonis UA. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Frontiers in Oncol. 2013;3:296. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3858677&tool=pmcentrez&rendertype=abstract .","DOI":"10.3389\/fonc.2013.00296"},{"key":"4290_CR13","doi-asserted-by":"crossref","unstructured":"Verschoor ML, Singh G. Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer. Mol Cancer. 2013;12:138. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3842663&tool=pmcentrez&rendertype=abstract .","DOI":"10.1186\/1476-4598-12-138"},{"key":"4290_CR14","doi-asserted-by":"crossref","unstructured":"Chaney SG, Campbell SL, Temple B, Bassett E, Wu Y, Faldu M. Protein interactions with platinum-DNA adducts: from structure to function. J Inorg Biochem. 2004;98:1551\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15458816 .","DOI":"10.1016\/j.jinorgbio.2004.04.024"},{"key":"4290_CR15","doi-asserted-by":"crossref","unstructured":"Goodisman J, Hagrman D, Tacka KA, Souid A-K. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol. 2006;57:257\u201367. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16028101 .","DOI":"10.1007\/s00280-005-0041-4"},{"key":"4290_CR16","doi-asserted-by":"crossref","unstructured":"Unger FT, Klasen HA, Tchartchian G, de Wilde RL, Witte I. DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer. 2009;9:359. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2768745&tool=pmcentrez&rendertype=abstract .","DOI":"10.1186\/1471-2407-9-359"},{"key":"4290_CR17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307\u201320.","journal-title":"Nat Rev Drug Discov"},{"key":"4290_CR18","unstructured":"Dhivya H. Glutathione\u2014a master antioxidant and an immune system modulator. 2012;1:13\u20135."},{"key":"4290_CR19","doi-asserted-by":"crossref","unstructured":"Mat\u00e9s JM, Segura JA, Mart\u00edn-Rufi\u00e1n M, Campos-Sandoval JA, Alonso FJ, M\u00e1rquez J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Current Mol Med. 2013;13:514\u201334. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22934847 .","DOI":"10.2174\/1566524011313040005"},{"key":"4290_CR20","doi-asserted-by":"crossref","unstructured":"Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP. Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(-\/-) knockout mouse. Novel model system for a severely compromised oxidative stress response. J Biol Chem. 2002;277:49446\u201352. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12384496 .","DOI":"10.1074\/jbc.M209372200"},{"key":"4290_CR21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.mam.2008.08.009","volume":"30","author":"CC Franklin","year":"2010","unstructured":"Franklin CC, Backosa DS, Moharb I, White CC, Formanc JH, et al. Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Mol Aspects Med. 2010;30:86\u201398.","journal-title":"Mol Aspects Med"},{"key":"4290_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200059004-00001","volume":"59","author":"LR Kelland","year":"2000","unstructured":"Kelland LR. Preclinical perspectives on platinum resistance. Drugs. 2000;59:1\u20138.","journal-title":"Drugs"},{"key":"4290_CR23","doi-asserted-by":"crossref","unstructured":"Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006;43:143\u201381. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16517421 .","DOI":"10.1080\/10408360500523878"},{"key":"4290_CR24","doi-asserted-by":"crossref","unstructured":"Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, et al. Role of glutathione in cancer progression and chemoresistance. Oxidative medicine and cellular longevity [Internet]. 2013;2013:972913. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3673338&tool=pmcentrez&rendertype=abstract","DOI":"10.1155\/2013\/972913"},{"key":"4290_CR25","unstructured":"Corti A, Franzini M, Paolicchi A, Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30:1169\u201381. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20530424\/RefSource> ."},{"key":"4290_CR26","doi-asserted-by":"crossref","unstructured":"Serpa J, Dias S. Metabolic cues from the microenvironment act as a major selective factor for cancer progression and metastases formation. Cell Cycle. 2011;10:180\u20131. Available from: http:\/\/www.landesbioscience.com\/journals\/cc\/article\/14476\/ .","DOI":"10.4161\/cc.10.2.14476"},{"key":"4290_CR27","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell Elsevier Inc. 2011;144:646\u201374. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21376230 .","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"4290_CR28","doi-asserted-by":"crossref","unstructured":"Dang CV. Glutaminolysis: supplying carbon or nitrogen, or both for cancer cells? Cell Cycle. 2010;9:3884\u20136. Available from: http:\/\/www.landesbioscience.com\/journals\/cc\/article\/13302\/ .","DOI":"10.4161\/cc.9.19.13302"},{"key":"4290_CR29","unstructured":"Reynolds MR, Lane a N, Robertson B, Kemp S, Liu Y, Hill BG, et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene [Internet]. Nature Publishing Group; 2013 [cited 2013 Jul 6];1\u201311. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23353822"},{"key":"4290_CR30","doi-asserted-by":"crossref","unstructured":"Fath MA, Ahmad IM, Smith CJ, Spence J, Spitz DR. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:6206\u201317. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid =3186854&tool=pmcentrez&rendertype=abstract .","DOI":"10.1158\/1078-0432.CCR-11-0736"},{"key":"4290_CR31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2131\/jts.28.455","volume":"28","author":"T Watanabe","year":"2003","unstructured":"Watanabe T, Sagisaka H, Arakawa S, Shibaya Y, Watanabe M. A novel model of continuous depletion of glutathione in mice with L-butathione (S, R)-sulfoximine. J Toxicol Sci Toxicol Sci. 2003;28:455\u201369.","journal-title":"J Toxicol Sci Toxicol Sci"},{"key":"4290_CR32","first-page":"6885","volume":"52","author":"C Meijer","year":"1992","unstructured":"Meijer C, Mulder NH, Timmer-bosscha H. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds1. Cancer Res. 1992;52:6885\u20139.","journal-title":"Cancer Res"},{"key":"4290_CR33","doi-asserted-by":"crossref","unstructured":"Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Seminars in cell & developmental biology. Elsevier Ltd; 2012;23:362\u20139. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid =3186854&tool=pmcentrez&rendertype=abstract .","DOI":"10.1016\/j.semcdb.2012.02.002"},{"key":"4290_CR34","doi-asserted-by":"crossref","unstructured":"Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013;4:1628. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3848248&tool=pmcentrez&rendertype=abstract .","DOI":"10.1038\/ncomms2629"},{"key":"4290_CR35","doi-asserted-by":"crossref","unstructured":"Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D\u2019Ascenzo S, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65:9369\u201376. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16230400 .","DOI":"10.1158\/0008-5472.CAN-05-1146"},{"key":"4290_CR36","doi-asserted-by":"crossref","unstructured":"Ridgway ND. The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Crit Rev Biochem Mol Biol. 2013;48:20\u201338. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16230400 .","DOI":"10.3109\/10409238.2012.735643"},{"key":"4290_CR37","doi-asserted-by":"crossref","unstructured":"Isra\u00ebl M, Schwartz L. The metabolic advantage of tumor cells. Molecular cancer [Internet]. BioMed Central Ltd; 2011 [cited 2013 May 31];10:70. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3118193&tool=pmcentrez&rendertype=abstract","DOI":"10.1186\/1476-4598-10-70"},{"key":"4290_CR38","first-page":"152","volume":"152","author":"SL Blair","year":"1997","unstructured":"Blair SL, Heerdt P, Sachar S, Aboihoda A, Hochwald S, Cheng H, et al. Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res. 1997;152:152\u20136.","journal-title":"Cancer Res"},{"key":"4290_CR39","doi-asserted-by":"crossref","unstructured":"Wu JH, Batist G. Glutathione and glutathione analogues; therapeutic potentials. Biochimica et biophysica acta [Internet]. Elsevier B.V.; 2013 [cited 2015 Feb 26];1830:3350\u20133. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23201199","DOI":"10.1016\/j.bbagen.2012.11.016"},{"key":"4290_CR40","doi-asserted-by":"crossref","unstructured":"Husain K, Whitworth C, Somani SM, Rybak LP. Carboplatin-induced oxidative stress in rat cochlea. Hear Res. 2001;159:14\u201322. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11520631 .","DOI":"10.1016\/S0378-5955(01)00306-9"},{"key":"4290_CR41","doi-asserted-by":"crossref","unstructured":"Quintana E, Pertusa J, Gonz\u00e1lez R, Renau-Piqueras J. Carboplatin treatment induces dose-dependent increases in the frequency of micronuclei in Ehrlich ascites tumor cells. Mutat Res. 1994;322:55\u201360. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7517504 .","DOI":"10.1016\/0165-1218(94)90032-9"},{"key":"4290_CR42","doi-asserted-by":"crossref","unstructured":"Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma. Am J Pathol Am Soc Investig Pathol. 2003;163:2503\u201312. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000294401063605X .","DOI":"10.1016\/S0002-9440(10)63605-X"},{"key":"4290_CR43","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.1074\/jbc.M211558200","volume":"278","author":"J-M Lee","year":"2003","unstructured":"Lee J-M, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem. 2003;278:12029\u201338.","journal-title":"J Biol Chem"},{"key":"4290_CR44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bcp.2008.10.006","volume":"77","author":"SS Singhal","year":"2009","unstructured":"Singhal SS, Yadav S, Roth C, Singhal J. RLIP76: a novel glutathione-conjugate and multi-drug transporter. Biochem Pharmacol. 2009;77:761\u20139. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid =2664079&tool=pmcentrez&rendertype=abstract .","journal-title":"Biochem Pharmacol"},{"key":"4290_CR45","doi-asserted-by":"crossref","unstructured":"Pompella A, De Tata V, Paolicchi A, Zunino F. Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol. 2006;71:231\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16303117 .","DOI":"10.1016\/j.bcp.2005.10.005"},{"key":"4290_CR46","first-page":"278","volume":"28","author":"E Jerremalm","year":"2006","unstructured":"Jerremalm E, Wallin I, Yachnin J, Ehrsson H. Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate. European J Pharm Sci Off J European Federation for Pharm Sci. 2006;28:278\u201383.","journal-title":"European J Pharm Sci Off J European Federation for Pharm Sci"},{"key":"4290_CR47","first-page":"5427","volume":"44","author":"JA Green","year":"1984","unstructured":"Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 1984;44:5427\u201331.","journal-title":"Cancer Res"},{"key":"4290_CR48","first-page":"2845","volume":"46","author":"A Russo","year":"1986","unstructured":"Russo A, Degraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res. 1986;46:2845\u20138.","journal-title":"Cancer Res"},{"key":"4290_CR49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F","volume":"60","author":"A Fojo","year":"1987","unstructured":"Fojo A, Hamilton T, Young R, Ozols R. Multidrug resistance in ovarian cancer. Cancer. 1987;60:2075\u201380.","journal-title":"Cancer"},{"key":"4290_CR50","doi-asserted-by":"crossref","unstructured":"Nolin TD, McMenamin ME, Himmelfarb J. Simultaneous determination of total homocysteine, cysteine, cysteinylglycine, and glutathione in human plasma by high-performance liquid chromatography: application to studies of oxidative stress. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:554\u201361. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid = 1959569&tool=pmcentrez&rendertype=abstract .","DOI":"10.1016\/j.jchromb.2007.02.024"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4290-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-4290-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4290-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T05:07:22Z","timestamp":1567314442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-4290-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,31]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["4290"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-4290-5","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,31]]}}}